Novartis Revolutionizes US Healthcare with Direct-to-Patient Drug Access
Novartis is set to revolutionise US healthcare with the launch of its direct-to-patient (DTP) platform on November 1, 2025. The Swiss pharmaceutical giant aims to remove barriers in the US healthcare system by offering patients direct access to its medications, starting with the best-selling drug, Cosentyx.
Cosentyx, a biologic drug approved for treating various immune-mediated inflammatory diseases, will be sold directly to cash-paying patients through the DTP platform. Patients will benefit from a significant discount of approximately 55% off the list price. This move by Novartis follows Amgen's earlier announcement to sell the same drug directly to patients in the USA, offering a 30% discount.
The DTP platform is designed to provide patients with a more affordable and convenient way to access their medications. By cutting out middlemen, Novartis hopes to make its drugs more accessible and reduce the financial burden on patients. The company plans to apply this offering to other drugs in its portfolio in the future.
Starting November 1, 2025, patients in the US will have direct access to Cosentyx through Novartis' DTP platform, with a substantial discount on the list price. This initiative marks a significant step towards improving patient access to medications and reducing healthcare costs in the US. Novartis plans to expand this offering to other drugs in the future, further transforming the US healthcare landscape.
